C3G/Primary IC-MPGN EAP

Sponsor
Apellis Pharmaceuticals, Inc.
Study ID
NCT04729062
Status
Approved For Marketing

Conditions

  • C3 Glomerulonephritis
  • C3 Glomerulopathy
  • C3G
  • Complement 3 Glomerulonephritis
  • Complement 3 Glomerulopathy
  • Complement 3 Glomerulopathy (C3G)
  • DDD
  • Dense Deposit Disease
  • IC-MPGN
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
  • Membranoproliferative Glomerulonephritis
  • Membranoproliferative Glomerulonephritis (MPGN)

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.

Key Dates

Status verified
Jul 2025

Related Studies